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Pulmonary hypertension (PH) is usually characterized by
excessive pulmonary vasoconstriction. Progression of PH
is also associated with remodeling of the pulmonary vas-
cular wall, localized thrombosis, and right heart hypertro-
phy and failure. Impaired bioavailability and/or
responsiveness to endogenous NO and other vasodilators
has been implicated in the pathogenesis of PH.
Pharmacological, NO-independent sGC agonists have
been evaluated in several models of PH. Intravenous
administration of the sGC stimulator BAY 41–2272 atten-
uates pulmonary vasoconstriction in ovine models of
acute chemically-induced PH and persistent PH of the
newborn. In rodent models of hypoxia- or monocrota-
line-induced PH, oral treatment or intramuscular injec-
tions of BAY 41–2272 or oral administration of the sGC
activator BAY 58–2667 attenuates the increase of right
ventricular systolic pressure, right ventricular hypertro-
phy, and structural remodeling of the lung vasculature.
Targeted drug delivery to the lungs by inhalation results in
high local bioavailability and a rapid onset of action at a
reduced drug dose, and therefore avoids or reduces sys-
temic side-effects. In sheep with acute PH, inhalation of
the sGC agonists (BAY 41–2272, BAY 41–8543, or BAY
58–2667) encapsulated into dry-powder microparticles
produces dose-dependent pulmonary vasodilation associ-
ated with increased transpulmonary cGMP release and
improves arterial oxygenation without a significant reduc-
tion of systemic arterial pressure. Moreover, when vasodi-
lator response to inhaled NO is impaired following
oxidation of the prosthetic heme group of sGC by ODQ,
both pulmonary vasodilation and transpulmonary cGMP
release induced by inhaling BAY 58–2667 microparticles
are greatly increased.
Taken together, these pre-clinical studies provide strong
evidence that pharmacological agonists of sGC may pro-
vide a lung selective treatment modality for patients with
PH particularly when endogenous NO-sGC-cGMP signal-
ing is impaired.
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